[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 9 of about 9
1. Mellor PJ, Polton GA, Brearley M, Haugland S, Smith KC, Scase TJ, McNeil PE, Holloway A, Archer J, Powell RM, Villiers EJ, Herrtage ME, Argyle DJ, Day MJ: Solitary plasmacytoma of bone in two successfully treated cats. J Feline Med Surg; 2007 Feb;9(1):72-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Solitary plasmacytoma of bone in two successfully treated cats.
  • This is the first report of feline solitary plasmacytoma of bone.
  • Clinical signs resolved completely and 4 years after diagnosis the cat remains well and has no electrophoretically detectable paraproteinaemia.
  • A biopsy of sacral bone demonstrated neoplastic plasma cell infiltration.
  • The cat improved clinically with induction chemotherapy (melphalan and methylprednisolone).
  • The same chemotherapeutics were continued at maintenance doses for 4.3 years, at which time there was recurrence of neurological deficits and a palpable sacral mass.
  • Eighteen months into vincristine therapy, there was recurrence of clinical signs and the cat was euthanased, more than 6 years after the initial diagnosis.
  • [MeSH-major] Cat Diseases / diagnosis. Cat Diseases / therapy. Plasmacytoma / veterinary. Spinal Neoplasms / veterinary
  • [MeSH-minor] Animals. Cats. Combined Modality Therapy. Female. Follow-Up Studies. Male. Treatment Outcome

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16887373.001).
  • [ISSN] 1098-612X
  • [Journal-full-title] Journal of feline medicine and surgery
  • [ISO-abbreviation] J. Feline Med. Surg.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  •  go-up   go-down


2. Dimopoulos MA, Moulopoulos LA, Maniatis A, Alexanian R: Solitary plasmacytoma of bone and asymptomatic multiple myeloma. Blood; 2000 Sep 15;96(6):2037-44
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Solitary plasmacytoma of bone and asymptomatic multiple myeloma.
  • Most patients with multiple myeloma (MM) present with symptoms, have evidence of generalized disease, and require chemotherapy promptly to reduce the malignant clone.
  • Some patients present with a local symptom from a single plasmacytoma but no myeloma elsewhere.
  • In patients with MM without symptoms, the diagnosis is made on the basis of screening laboratory tests.
  • In patients with either solitary plasmacytoma of bone or asymptomatic MM, systemic treatment should be deferred until there is evidence of disease progression.
  • [MeSH-major] Bone Neoplasms. Multiple Myeloma. Plasmacytoma


3. Wilder RB, Ha CS, Cox JD, Weber D, Delasalle K, Alexanian R: Persistence of myeloma protein for more than one year after radiotherapy is an adverse prognostic factor in solitary plasmacytoma of bone. Cancer; 2002 Mar 1;94(5):1532-7
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Persistence of myeloma protein for more than one year after radiotherapy is an adverse prognostic factor in solitary plasmacytoma of bone.
  • BACKGROUND: Prognostic factors for solitary plasmacytoma of bone (SPB), whether measured before or after radiotherapy (RT), have not been established.
  • The authors analyzed multiple factors for myeloma-free survival (MFS) and cause-specific survival (CSS) in SPB patients treated with RT alone.
  • Patient ages ranged from 29-77 years (median, 54 years), and 75% of patients had a myeloma (M) protein in the blood and/or urine.
  • Radiotherapy to the solitary lesion was given to a total dose of 30-70 Gy (median, 46 Gy).
  • The authors analyzed the impact of multiple factors on MFS and CSS, including resolution v. persistence of M protein after RT, secretory v. nonsecretory disease at diagnosis, presence v. absence of an associated soft tissue mass on computed tomography or MRI scan, magnitude of serum M protein elevation at diagnosis, age, spinal v. nonspinal location, Karnofsky performance status, total RT dose, and tumor size.
  • On multivariate analysis, persistence of M protein more than one year after RT was the only independent adverse prognostic factor for MFS (P = 0.005) and CSS (P = 0.04).
  • Most patients with M protein that persisted for more than one year after RT were diagnosed with multiple myeloma within 2.2 years of treatment.
  • CONCLUSIONS: Patients with M protein that persists for more than one year after RT should be monitored frequently and considered for standard chemotherapy followed by intensive consolidation therapy when they either develop symptoms or show an increasing M protein level.
  • [MeSH-major] Bone Neoplasms / pathology. Bone Neoplasms / radiotherapy. Multiple Myeloma / pathology. Myeloma Proteins / analysis. Plasmacytoma / pathology. Plasmacytoma / radiotherapy
  • [MeSH-minor] Adult. Aged. Disease-Free Survival. Female. Follow-Up Studies. Humans. Magnetic Resonance Imaging. Male. Middle Aged. Prognosis. Time Factors. Tomography, X-Ray Computed

  • MedlinePlus Health Information. consumer health - Bone Cancer.
  • MedlinePlus Health Information. consumer health - Multiple Myeloma.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2002 American Cancer Society.
  • (PMID = 11920511.001).
  • [ISSN] 0008-543X
  • [Journal-full-title] Cancer
  • [ISO-abbreviation] Cancer
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / CA 16672; United States / NCI NIH HHS / CA / CA 6294
  • [Publication-type] Journal Article; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Myeloma Proteins; 0 / multiple myeloma M-proteins
  •  go-up   go-down


Advertisement
4. Ota K, Tsuda T, Katayama N, Sakaguchi R, Hara I, Hayashi H, Okamoto Y: A therapeutic strategy for isolated plasmacytoma of bone. J Int Med Res; 2001 Jul-Aug;29(4):366-73
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A therapeutic strategy for isolated plasmacytoma of bone.
  • Two cases of solitary plasmacytoma of bone (SPB) were diagnosed.
  • Magnetic resonance imaging showed the osteolytic lesion in the 12th thoracic bone in the first patient and around the 2nd, 3rd and 4th lumbar bones in the second patient.
  • Both patients were first treated with irradiation around the involved bone and then with a course of chemotherapy.
  • In the first patient the tumour region of the bone was surgically removed and replaced with a ceramic spacer.
  • The symptoms of both patients were ameliorated, and the patients remained in good condition for around 3 years without conversion to multiple myeloma.
  • In view of the overall effectiveness of treatments for SPB, our therapeutic strategy deserves careful evaluation.
  • [MeSH-major] Bone Neoplasms / therapy. Plasmacytoma / therapy
  • [MeSH-minor] Adult. Bone Marrow / pathology. Combined Modality Therapy. Female. Humans. Immunoglobulins / blood. Lumbar Vertebrae. Male. Middle Aged. Thoracic Vertebrae

  • MedlinePlus Health Information. consumer health - Bone Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11675911.001).
  • [ISSN] 0300-0605
  • [Journal-full-title] The Journal of international medical research
  • [ISO-abbreviation] J. Int. Med. Res.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Immunoglobulins
  •  go-up   go-down


5. Mendenhall WM, Mendenhall CM, Mendenhall NP: Solitary plasmacytoma of bone and soft tissues. Am J Otolaryngol; 2003 Nov-Dec;24(6):395-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Solitary plasmacytoma of bone and soft tissues.
  • PURPOSE: To define the optimal treatment and outcomes for patients with solitary plasmacytoma of bone and soft tissue.
  • RESULTS: Solitary plasmacytomas are uncommon and account for less than 5% of plasma cell neoplasms.
  • Solitary plasmacytomas of bone (SPB) usually occur in the vertebra and skull and are more common than extramedullary plasmacytomas (EMP) that almost always arise in the head and neck and may spread to regional lymph nodes.
  • The optimal treatment is moderate-dose radiotherapy (40-50 Gy) and occasionally surgery.
  • Adjuvant chemotherapy does not improve survival.
  • Patients with EMP have a relatively low risk of progressing to multiple myeloma and have improved survival compared with those who present with SPB.
  • CONCLUSION: Solitary plasmacytoma is an uncommon neoplasm that often arises in the head and neck.
  • Optimal treatment is moderate-dose radiotherapy.
  • [MeSH-major] Bone Neoplasms / therapy. Plasmacytoma / therapy. Soft Tissue Neoplasms / therapy
  • [MeSH-minor] Female. Humans. Male. Prognosis. Survival Rate. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Bone Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 14608572.001).
  • [ISSN] 0196-0709
  • [Journal-full-title] American journal of otolaryngology
  • [ISO-abbreviation] Am J Otolaryngol
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 23
  •  go-up   go-down


6. Tsang RW, Gospodarowicz MK, Pintilie M, Bezjak A, Wells W, Hodgson DC, Stewart AK: Solitary plasmacytoma treated with radiotherapy: impact of tumor size on outcome. Int J Radiat Oncol Biol Phys; 2001 May 1;50(1):113-20
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Solitary plasmacytoma treated with radiotherapy: impact of tumor size on outcome.
  • PURPOSE: Solitary plasmacytoma (SP) is a rare presentation of plasma cell neoplasms.
  • In contrast to multiple myeloma, long-term disease-free survival and cure is possible following local radiotherapy (RT), particularly for soft tissue presentations.
  • In this study, we attempt to identify factors that predict for local failure, progression to multiple myeloma, and disease-free survival (DFS) in patients mainly managed with local RT.
  • All patients had biopsy-proven SP (osseous: 32, soft tissue: 14).
  • All patients were treated with local RT (median dose 35 Gy), with 5 patients (11%) also receiving chemotherapy.
  • RESULTS: The 8-year overall survival, DFS, and myeloma-free rates were 65%, 44%, and 50%, respectively.
  • Factors predictive of progression to myeloma (and poorer DFS) included bone presentation and older age.
  • Lower RT dose (< or =35 Gy) was not associated with a higher risk of local failure.
  • CONCLUSION: Solitary plasmacytomas are effectively treated with moderate-dose RT, although osseous tumors have a high rate of recurrence as systemic myeloma.
  • Combined chemotherapy and RT should be investigated in these high-risk patients to increase the local control rate and the cure rate.
  • [MeSH-major] Plasmacytoma / pathology. Plasmacytoma / radiotherapy
  • [MeSH-minor] Adult. Aged. Disease Progression. Disease-Free Survival. Dose-Response Relationship, Radiation. Female. Humans. Male. Middle Aged. Multiple Myeloma / pathology. Multiple Myeloma / radiotherapy. Survival Rate. Treatment Outcome

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11316553.001).
  • [ISSN] 0360-3016
  • [Journal-full-title] International journal of radiation oncology, biology, physics
  • [ISO-abbreviation] Int. J. Radiat. Oncol. Biol. Phys.
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


7. Dagan R, Morris CG, Kirwan J, Mendenhall WM: Solitary plasmacytoma. Am J Clin Oncol; 2009 Dec;32(6):612-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Solitary plasmacytoma.
  • PURPOSE: To analyze the outcomes of patients treated for solitary plasmacytoma with definitive radiotherapy (RT).
  • MATERIAL AND METHODS: Thirty-two patients with solitary plasmacytoma of bone (SPB; 22 patients) and extramedullary plasmacytoma (EMP; 10 patients) were treated between 1963 and 2006.
  • The median RT dose was around 42.7 Gy (range, 15-54 Gy) over a median of 25 fractions (range, 1-32 fractions).
  • No patient received adjuvant chemotherapy.
  • All 4 patients who developed a local recurrence had SPBs > or = 5 cm.
  • The 10-year multiple myeloma-free survival rates were: SPB, 30%; EMP, 90%; and overall, 50%.
  • Progression to multiple myeloma occurred at a median of 25.1 months after RT.
  • Patients with SPB are more likely to progress to multiple myeloma, which adversely affects their survival compared with those with EMP.
  • [MeSH-major] Bone Neoplasms / radiotherapy. Plasmacytoma / radiotherapy
  • [MeSH-minor] Female. Follow-Up Studies. Humans. Male. Maximum Tolerated Dose. Middle Aged. Multiple Myeloma / pathology. Multiple Myeloma / radiotherapy. Prognosis. Survival Rate. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Bone Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19593082.001).
  • [ISSN] 1537-453X
  • [Journal-full-title] American journal of clinical oncology
  • [ISO-abbreviation] Am. J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


8. Bampoe J, Nag S, Leung P, Laperriere N, Bernstein M: Brain necrosis after permanent low-activity iodine-125 implants: case report and review of toxicity from focal radiation. Brain Tumor Pathol; 2000;17(3):139-45
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Focal irradiation has emerged as a useful modality in the management of malignant brain tumors.
  • We report on the radiation dose distribution in the cerebellum of a patient who developed imaging and autopsy diagnosis of radiation necrosis after permanent iodine-125 implants for a solitary osseous plasmacytoma of her left occipital condyle.
  • A cytological diagnosis of solitary osseous plasmacytoma was made by transpharyngeal needle biopsy.
  • After an initial course of external beam radiation, the patient required further treatment with systemic chemotherapy 21 months later for clinical and radiographic progression of her disease.
  • She ultimately required subtotal surgical resection of an anaplastic plasmacytoma with intracranial extension.
  • Progressive systemic myeloma led to her death 11 years after presentation and 9 years after seed implantation.
  • [MeSH-minor] Algorithms. Cranial Nerves / pathology. Drug Implants. Female. Humans. Magnetic Resonance Imaging. Middle Aged. Necrosis. Plasmacytoma / pathology. Plasmacytoma / radiotherapy. Skull Base Neoplasms / pathology. Skull Base Neoplasms / radiotherapy

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11310921.001).
  • [ISSN] 1433-7398
  • [Journal-full-title] Brain tumor pathology
  • [ISO-abbreviation] Brain Tumor Pathol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Drug Implants; 0 / Iodine Radioisotopes
  •  go-up   go-down


9. Khaliq W, Uzoaru I, Konchanin RP, Sapiente RA, Egner JR: Solitary extramedullary plasmacytoma of the bladder: a case report and literature. Oncology (Williston Park); 2010 Aug;24(9):832-5
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Solitary extramedullary plasmacytoma of the bladder: a case report and literature.
  • Plasmacytoma is a rare B-lymphocyte neoplastic disorder that usually presents as the generalized disease multiple myeloma.
  • Less than 5% of the cases present as a solitary mass of monoclonal plasma cells in the bone or soft tissue.
  • Although solitary extramedullary plasmacytoma (SEP) may arise in any organ, it rarely involves the urinary bladder.
  • A 67-year-old male without a history of multiple myeloma presented with urinary frequency and nocturia; he was later diagnosed with SEP of the bladder.
  • The patient was initially treated with a course of radiation therapy without symptomatic improvement; therefore a chemotherapy regimen consisting of lenalidomide and dexamethasone was subsequently given for six cycles.
  • SEP usually carries a better prognosis and higher cure rate than solitary plasmacytoma of bone, as SEP is radiation sensitive.
  • The role of adjuvant chemotherapy in the treatment of SEP that is resistant to radiation therapy is not clear, since most of the recommendations have been derived from the experience of head and neck SEP.
  • The literature also lacks recommendations for choice of a chemotherapy regimen and surveillance of isolated bladder plasmacytoma.
  • Here we present the first case of a radiation-resistant solitary plasmacytoma of the bladder that was successfully treated with lenalidomide and dexamethasone with successful clinical remission.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols. Plasmacytoma. Radiotherapy. Urinary Bladder Neoplasms
  • [MeSH-minor] Aged. Biopsy. Cystoscopy. Dexamethasone / administration & dosage. Humans. Male. Radiation Tolerance. Remission Induction. Thalidomide / administration & dosage. Thalidomide / analogs & derivatives. Treatment Failure. Urinary Bladder / pathology. Urinary Bladder / physiopathology

  • MedlinePlus Health Information. consumer health - Bladder Cancer.
  • MedlinePlus Health Information. consumer health - Radiation Therapy.
  • Hazardous Substances Data Bank. DEXAMETHASONE .
  • Hazardous Substances Data Bank. THALIDOMIDE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Oncology (Williston Park). 2010 Aug;24(9):836 [20923038.001]
  • [CommentIn] Oncology (Williston Park). 2010 Aug;24(9):838 [20923039.001]
  • (PMID = 20923037.001).
  • [ISSN] 0890-9091
  • [Journal-full-title] Oncology (Williston Park, N.Y.)
  • [ISO-abbreviation] Oncology (Williston Park, N.Y.)
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 4Z8R6ORS6L / Thalidomide; 7S5I7G3JQL / Dexamethasone; F0P408N6V4 / lenalidomide
  •  go-up   go-down






Advertisement